Calyx Partnership with Top 5 CRO Extended through 2024
Calyx has announced an extended partnership with one of the world’s Top 5 clinical research organizations (CRO). The arrangement enables the leading CRO to continue providing Calyx’s proven clinical trial management system (CTMS) and services to its global biopharmaceutical customers for an additional three years. The CRO selected Calyx CTMS based on its use of Microsoft’s Azure cloud technology.
Calyx CTMS enables its 8,000+ users to centralize operational data for informed decision making and improve the management of clinical trials with tools that address the complexities of traditional and decentralized trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
